L-pred Ophthalmic Suspension contains Loteprednol etabonate 0.5% w/v, a corticosteroid indicated for the treatment of inflammation and pain associated with ocular conditions such as postoperative inflammation following ocular surgery, allergic conjunctivitis, and anterior uveitis. Loteprednol etabonate is a corticosteroid designed to provide potent anti-inflammatory effects while minimizing the risk of corticosteroid-related adverse events. The suspension formulation allows for effective drug delivery to the anterior segment of the eye, reducing inflammation by inhibiting multiple inflammatory mediators and cellular responses. L-pred Ophthalmic Suspension should be administered as directed by a healthcare professional, typically instilled into the affected eye(s) multiple times daily, with dosage adjusted based on clinical response. Caution is advised in patients with ocular infections, glaucoma, or a history of corticosteroid-induced intraocular pressure elevation. Prolonged use may increase the risk of cataract formation and elevated intraocular pressure; therefore, regular monitoring is recommended. Patients should avoid contact lens use during treatment unless otherwise instructed. L-pred Ophthalmic Suspension is contraindicated in viral, fungal, or mycobacterial ocular infections. Proper administration technique and adherence to prescribed dosing schedules are essential to optimize therapeutic outcomes and minimize adverse effects.